StrataCTX® as a Steroid Sparing Device
Post-marketing Surveillance of StrataCTX® Flexible Wound Dressing for Use as a Steroid Sparing Agent
Columbia University
70 participants
Jul 7, 2021
INTERVENTIONAL
Conditions
Summary
The purpose is to determine if StrataCTX® can be used as a steroid sparing agent for the treatment of cutaneous reactions related to, cutaneous T Cell lymphoma (CTCL) and chemotherapy/immunotherapy treatments than the current standard treatment - topical steroids - in people who are receiving treatment for CTCL, or chemotherapy/immunotherapy for solid/hematologic malignancies. Subjects will have CTCL and are being treated with topical steroids, or being treated with chemotherapy/immunotherapy for another condition and have had cutaneous reactions that have warranted initiation of topical steroids.
Eligibility
Inclusion Criteria6
- Age ≥ 18 years
- Ability to sign informed consent document
- Patient with a diagnosis of CTCL who have contact dermatitis to topical mechlorethamine gel
- Patients with a diagnosis of CTCL who have intractable pruritis
- Patients with a diagnosis of CTCL who rely heavily on topical steroids for symptomatic relief
- Patients on chemo/immunotherapy with drug induced rash
Exclusion Criteria3
- Patients currently undergoing radiotherapy
- Patients currently receiving oral steroids
- Patients who are unable to apply topical medications
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Gel forming flexible wound dressing for the prevention and treatment of radiation dermatitis
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04087629